DOP2002000336A - Inhibidores de benzotiadiazina de metaloproteinasas de la matriz - Google Patents
Inhibidores de benzotiadiazina de metaloproteinasas de la matrizInfo
- Publication number
- DOP2002000336A DOP2002000336A DO2002000336A DO2002000336A DOP2002000336A DO P2002000336 A DOP2002000336 A DO P2002000336A DO 2002000336 A DO2002000336 A DO 2002000336A DO 2002000336 A DO2002000336 A DO 2002000336A DO P2002000336 A DOP2002000336 A DO P2002000336A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- inhibitors
- benzotiadiazine
- metaloproteinases
- matrix
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 102100027995 Collagenase 3 Human genes 0.000 abstract 2
- 108050005238 Collagenase 3 Proteins 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000007658 benzothiadiazines Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Manufacture Of Alloys Or Alloy Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26878201P | 2001-02-14 | 2001-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2002000336A true DOP2002000336A (es) | 2003-01-31 |
Family
ID=23024450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2002000336A DOP2002000336A (es) | 2001-02-14 | 2002-02-01 | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6656932B2 (enExample) |
| EP (1) | EP1368327B1 (enExample) |
| JP (1) | JP2004518726A (enExample) |
| AT (1) | ATE280164T1 (enExample) |
| BR (1) | BR0207865A (enExample) |
| CA (1) | CA2433075A1 (enExample) |
| DE (1) | DE60201665T2 (enExample) |
| DO (1) | DOP2002000336A (enExample) |
| ES (1) | ES2231708T3 (enExample) |
| GT (1) | GT200200016A (enExample) |
| HN (1) | HN2002000227A (enExample) |
| MX (1) | MXPA03005870A (enExample) |
| PA (1) | PA8538501A1 (enExample) |
| PE (1) | PE20020953A1 (enExample) |
| TN (1) | TNSN02013A1 (enExample) |
| UY (1) | UY27155A1 (enExample) |
| WO (1) | WO2002064578A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| AU2003281169A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| JP2006502114A (ja) * | 2002-07-17 | 2006-01-19 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリクスメタロプロテイナーゼ−１３のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ |
| EP1531904A1 (en) * | 2002-07-17 | 2005-05-25 | Warner-Lambert Company LLC | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| MXPA05000729A (es) * | 2002-07-17 | 2005-04-08 | Warner Lambert Co | Combinacion de un inhibidor alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
| CA2492019A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Isoquinoline derivatives as matrix metalloproteinase inhibitors |
| BR0313384A (pt) | 2002-08-13 | 2005-07-12 | Warner Lambert Co | Derivados de cromona como inibidores de metaloproteinases de matriz |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| WO2004014868A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| BR0313459A (pt) | 2002-08-13 | 2005-06-21 | Warner Lambert Co | Derivados monocìclicos como inibidores de metaloproteinases de matriz |
| AU2003249539A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
| WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| WO2004014354A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| WO2004014866A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| JP2006503008A (ja) * | 2002-08-13 | 2006-01-26 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体 |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| WO2005002585A1 (en) * | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| WO2005016926A1 (en) * | 2003-08-19 | 2005-02-24 | Warner-Lambert Company Llc | Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| US7570259B2 (en) | 2004-06-01 | 2009-08-04 | Intel Corporation | System to manage display power consumption |
| EP1828152B1 (en) | 2004-12-08 | 2008-08-20 | Bristol-Myers Squibb Company | Heterocyclic compounds as inhibitors of factor viia |
| CA2602609A1 (en) * | 2005-03-16 | 2006-09-21 | Junichi Yokotani | Novel anthranilic acid derivative or salt thereof |
| HUE033442T2 (en) | 2009-06-25 | 2017-11-28 | Alkermes Pharma Ireland Ltd | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| EP3156056B1 (en) | 2011-03-18 | 2023-12-06 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| AU2013235526B2 (en) | 2012-03-19 | 2017-11-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| ES2792149T3 (es) | 2012-09-19 | 2020-11-10 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada |
| AU2015231278B2 (en) | 2014-03-20 | 2020-01-23 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
| CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN111454232B (zh) * | 2020-05-30 | 2021-11-23 | 南方医科大学 | 一种1,3,4-噻二嗪类化合物及其应用 |
| CN113773277B (zh) * | 2021-09-18 | 2023-12-05 | 兰州大学 | 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法 |
| AU2024248193A1 (en) | 2023-03-27 | 2025-10-09 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| WO2024206347A1 (en) * | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Fused thiadiazine dioxide compounds and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242443B1 (en) * | 1996-06-21 | 2001-06-05 | Novo Nordisk Ais | 1,2,4-benzothiadiazine derivatives, their preparation and use |
| MXPA99001974A (es) * | 1996-12-09 | 2002-03-27 | Warner Lambert Co | Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular. |
| ATE309991T1 (de) * | 1997-04-28 | 2005-12-15 | Us Health | Cyclin abhängige kinase(cdk)4 hemmer und deren verwendung zur behandlung von krebs |
| JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用 |
| WO2001009485A1 (en) | 1999-07-30 | 2001-02-08 | Yoshikane Ikitake | Reciprocating vane type rotary internal combustion engine |
| PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| KR20030061825A (ko) | 2000-10-26 | 2003-07-22 | 화이자 프로덕츠 인크. | 피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
| KR20040004412A (ko) | 2000-10-26 | 2004-01-13 | 화이자 프로덕츠 인크. | 스피로-피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제 |
| PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
-
2002
- 2002-01-11 MX MXPA03005870A patent/MXPA03005870A/es unknown
- 2002-01-11 JP JP2002564511A patent/JP2004518726A/ja not_active Abandoned
- 2002-01-11 ES ES02740094T patent/ES2231708T3/es not_active Expired - Lifetime
- 2002-01-11 DE DE60201665T patent/DE60201665T2/de not_active Expired - Fee Related
- 2002-01-11 EP EP02740094A patent/EP1368327B1/en not_active Expired - Lifetime
- 2002-01-11 CA CA002433075A patent/CA2433075A1/en not_active Abandoned
- 2002-01-11 BR BR0207865-1A patent/BR0207865A/pt not_active IP Right Cessation
- 2002-01-11 AT AT02740094T patent/ATE280164T1/de not_active IP Right Cessation
- 2002-01-11 WO PCT/IB2002/000083 patent/WO2002064578A1/en not_active Ceased
- 2002-02-01 DO DO2002000336A patent/DOP2002000336A/es unknown
- 2002-02-05 PA PA20028538501A patent/PA8538501A1/es unknown
- 2002-02-07 GT GT200200016A patent/GT200200016A/es unknown
- 2002-02-08 UY UY27155A patent/UY27155A1/es not_active Application Discontinuation
- 2002-02-11 HN HN2002000227A patent/HN2002000227A/es unknown
- 2002-02-12 PE PE2002000109A patent/PE20020953A1/es not_active Application Discontinuation
- 2002-02-13 US US10/074,646 patent/US6656932B2/en not_active Expired - Fee Related
- 2002-02-13 TN TNTNSN02013A patent/TNSN02013A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6656932B2 (en) | 2003-12-02 |
| CA2433075A1 (en) | 2002-08-22 |
| BR0207865A (pt) | 2004-03-23 |
| HN2002000227A (es) | 2002-10-23 |
| EP1368327B1 (en) | 2004-10-20 |
| US20020156069A1 (en) | 2002-10-24 |
| PE20020953A1 (es) | 2002-10-25 |
| DE60201665T2 (de) | 2006-02-02 |
| JP2004518726A (ja) | 2004-06-24 |
| TNSN02013A1 (fr) | 2005-12-23 |
| GT200200016A (es) | 2002-10-01 |
| UY27155A1 (es) | 2002-09-30 |
| ATE280164T1 (de) | 2004-11-15 |
| ES2231708T3 (es) | 2005-05-16 |
| EP1368327A1 (en) | 2003-12-10 |
| DE60201665D1 (de) | 2004-11-25 |
| PA8538501A1 (es) | 2002-09-17 |
| WO2002064578A1 (en) | 2002-08-22 |
| MXPA03005870A (es) | 2005-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2002000336A (es) | Inhibidores de benzotiadiazina de metaloproteinasas de la matriz | |
| EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| EA200200976A1 (ru) | Способ лечения или ингибирования полипов ободочной кишки | |
| ATE349435T1 (de) | Dpiv-inhibitoren auf glutaminbasis | |
| EA200100411A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| BR0010598A (pt) | Azoles substituìdos | |
| EA200500856A1 (ru) | Новые химические соединения | |
| NO953305D0 (no) | Antranilsyrederivat | |
| IS6309A (is) | Kínasólínafleiður | |
| EA199800579A1 (ru) | Новые производные 5-амино-3-циано-4-этилсульфинил-1-фенилпиразола и их применение в качестве пестицидов | |
| DK1485359T3 (da) | Natriumkanalblokkere | |
| BR9900177A (pt) | Inibidores de metaloprotease. | |
| TNSN02012A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| ES2189968T3 (es) | Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS. | |
| DE60002714D1 (de) | Substituierte azaoxindolederivate | |
| PA8477001A1 (es) | Inhibidores no peptidilicos de la union a las celulas dependientes de la vla-4 utiles en el tratamiento de enfermedades inflamatorias autoinmunes y respiratorias | |
| CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
| NZ507835A (en) | Heterocyclic derivatives which inhibit factor XA | |
| ATE347555T1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
| ES2193241T3 (es) | Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas. | |
| ATE496056T1 (de) | Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga | |
| EA200000996A1 (ru) | Конденсированные с арилом азаполициклические соединения | |
| DK0828721T3 (da) | 2-Aminobenzoxazinoner til behandling af virale infektioner | |
| EA200100040A1 (ru) | Химический синтез морфолиновых производных | |
| BR9902084A (pt) | Heterociclos. |